Proteomic profiling of urine for the detection of colon cancer.
BACKGROUND
Colorectal cancer is the second most common cause of cancer related death in the developed world. To date, no blood or stool biomarkers with both high sensitivity and specificity for potentially curable early stage disease have been validated for clinical use. SELDI and MALDI profiling are being used increasingly to search for biomarkers in both blood and urine. Both techniques provide information predominantly on the low molecular weight proteome (<15 kDa). There have been several reports that colorectal cancer is associated with changes in the serum proteome that are detectable by SELDI and we hypothesised that proteomic changes would also be detectable in urine.


RESULTS
We collected urine from 67 patients with colorectal cancer and 72 non-cancer control subjects, diluted to a constant protein concentration and generated MALDI and SELDI spectra. The intensities of 19 peaks differed significantly between cancer and non-cancer patients by both t-tests and after adjusting for confounders using multiple linear regressions. Logistic regression classifiers based on peak intensities identified colorectal cancer with up to 78% sensitivity at 87% specificity. We identified and independently quantified 3 of the discriminatory peaks using synthetic stable isotope peptides (an 1885 Da fragment of fibrinogen and hepcidin-20) or ELISA (beta2-microglobulin).


CONCLUSIONS
Changes in the urine proteome may aid in the early detection of colorectal cancer.
Ward
Douglas G
DG
Cancer Research UK Institute for Cancer Studies, University of Birmingham, Edgbaston, UK. d.g.ward@bham.ac.uk
Nyangoma
Stephen
S
Joy
Howard
H
Hamilton
Emma
E
Wei
Wenbin
W
Tselepis
Chris
C
Steven
Neil
N
Wakelam
Michael J O
MJ
Johnson
Philip J
PJ
Ismail
Tariq
T
Martin
Ashley
A